IN2012DN01965A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01965A
IN2012DN01965A IN1965DEN2012A IN2012DN01965A IN 2012DN01965 A IN2012DN01965 A IN 2012DN01965A IN 1965DEN2012 A IN1965DEN2012 A IN 1965DEN2012A IN 2012DN01965 A IN2012DN01965 A IN 2012DN01965A
Authority
IN
India
Prior art keywords
subject
subunit
administering
binding
provides methods
Prior art date
Application number
Other languages
English (en)
Inventor
Joaquin Mario Valdes
Elliot K Chartash
William T Barchuk
Susan K Paulson
Kenneth B Gordon
Walid M Awni
Yanjun Bao
William G Glass
Yihua Gu
Tom C Harris
Martin Kaul
Parvez M Mulani
Peter Noertersheuser
Martin M Okun
Kristen E Weiler
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of IN2012DN01965A publication Critical patent/IN2012DN01965A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IN1965DEN2012 2009-09-14 2010-09-14 IN2012DN01965A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24228809P 2009-09-14 2009-09-14
US24596709P 2009-09-25 2009-09-25
US29762310P 2010-01-22 2010-01-22
US36029910P 2010-06-30 2010-06-30
PCT/US2010/048771 WO2011032148A1 (en) 2009-09-14 2010-09-14 Methods for treating psoriasis

Publications (1)

Publication Number Publication Date
IN2012DN01965A true IN2012DN01965A (ja) 2015-08-21

Family

ID=43732849

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1965DEN2012 IN2012DN01965A (ja) 2009-09-14 2010-09-14

Country Status (15)

Country Link
US (2) US8557239B2 (ja)
EP (1) EP2477654A4 (ja)
JP (1) JP2013504598A (ja)
KR (2) KR20120112384A (ja)
CN (1) CN102630168A (ja)
AU (1) AU2010291927A1 (ja)
CA (1) CA2773556A1 (ja)
IL (1) IL218633A0 (ja)
IN (1) IN2012DN01965A (ja)
MX (1) MX2012003138A (ja)
NZ (1) NZ598722A (ja)
RU (1) RU2012114854A (ja)
SG (1) SG179135A1 (ja)
TW (1) TW201127400A (ja)
WO (1) WO2011032148A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN103813804A (zh) * 2010-10-06 2014-05-21 Abbvie公司 用于治疗银屑病的方法
MX2014000531A (es) * 2011-07-13 2014-12-05 Abbvie Inc Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
US20160060337A1 (en) * 2013-03-15 2016-03-03 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
AU2017332771A1 (en) * 2016-09-23 2019-04-04 Abbvie Inc. Dose adjustment
MA50580A (fr) * 2017-11-06 2020-09-16 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23
RU2697415C1 (ru) * 2018-11-12 2019-08-14 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения каплевидного псориаза
US20220298236A1 (en) * 2021-03-12 2022-09-22 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
EP4305062A1 (en) * 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) * 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2118066T3 (es) * 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US6683046B1 (en) * 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
DE122009000074I1 (de) * 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5562138A (en) * 1994-10-13 1996-10-08 The Longaberger Company Bowing press
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5670057A (en) 1995-04-28 1997-09-23 Baxter International Inc. Apparatus and method for automatically performing peritoneal equilibration tests
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) * 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU228630B1 (en) * 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
AU7257696A (en) 1996-10-11 1998-05-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
ES2213209T3 (es) 1996-11-15 2004-08-16 Kennedy Institute Of Rheumatology Supresion de tnfalfa e il-12 en terapia.
EP2314625B1 (en) * 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
ATE357459T1 (de) * 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
EP1336654A1 (en) * 1998-12-09 2003-08-20 Protein Design Labs, Inc. Method of treating psoriasis using anti-gamma interferon antibody
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
KR20130105766A (ko) * 1999-03-25 2013-09-25 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP5052736B2 (ja) * 2001-05-30 2012-10-17 中外製薬株式会社 タンパク質製剤
US20050276823A1 (en) * 2002-07-12 2005-12-15 Cini John K Methods and compositions for preventing oxidative degradation of proteins
US7608260B2 (en) * 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
EP1698640B2 (en) * 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
WO2005058294A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
WO2005077414A1 (de) * 2004-02-12 2005-08-25 Merck Patent Gmbh Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
SG158150A1 (en) * 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
HUE042561T2 (hu) * 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
KR20080098504A (ko) * 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
WO2008121301A1 (en) * 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
CN103813804A (zh) * 2010-10-06 2014-05-21 Abbvie公司 用于治疗银屑病的方法
TW201309330A (zh) * 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途

Also Published As

Publication number Publication date
US20140079714A1 (en) 2014-03-20
KR20120112384A (ko) 2012-10-11
AU2010291927A1 (en) 2012-04-12
KR20140048229A (ko) 2014-04-23
TW201127400A (en) 2011-08-16
IL218633A0 (en) 2012-05-31
EP2477654A4 (en) 2013-01-23
RU2012114854A (ru) 2013-10-27
CA2773556A1 (en) 2011-03-17
US8557239B2 (en) 2013-10-15
MX2012003138A (es) 2012-07-04
CN102630168A (zh) 2012-08-08
SG179135A1 (en) 2012-05-30
NZ598722A (en) 2014-05-30
US20110206680A1 (en) 2011-08-25
EP2477654A1 (en) 2012-07-25
JP2013504598A (ja) 2013-02-07
WO2011032148A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
IN2012DN01965A (ja)
MX2010010265A (es) Metodos para tratar psoriasis.
WO2012048134A3 (en) Methods for treating psoriasis
MX2009007570A (es) Metodos para tratar la psoriasis.
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
SG165322A1 (en) Engineered anti-il-23 antibodies
MX2011007930A (es) Conjugados de insulina cristalina.
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
NZ707086A (en) Anti-cd40 antibodies and methods of use
IN2012DN01920A (ja)
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MY162511A (en) Engineered anti-tslp antibody
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
WO2012076293A3 (de) Zubereitungen enthaltend polysiloxane mit stickstoffhaltigen gruppen
MX2011010955A (es) Terapia complementaria contra el cancer.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
NZ705008A (en) Novel modulators and methods of use
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
UA104663C2 (en) Antibody binding to cd127
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.